Biomea Fusion Inc
Veridion Score
Composite trend over time
Why is BMEA moving today?
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BMEA.
BMEA insider activity
Biomea Fusion Inc
No multi-insider buying cluster in the last 90 days
Net buying: $197K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | 2025-12-11 | Erdtmann Rainer M | Insider | buy | $1.43 | 30,000 | 723,027 | $43K | SEC Form 4 |
| 2025-12-04 | 2025-12-02 | Hitchcock Michael J.M. | Insider | buy | $0.99 | 100,000 | 115,000 | $99K | SEC Form 4 |
| 2025-12-02 | 2025-12-01 | Erdtmann Rainer M | Insider | buy | $1.05 | 10,000 | 693,027 | $11K | SEC Form 4 |
| 2025-12-02 | 2025-11-28 | Erdtmann Rainer M | Insider | buy | $1.10 | 40,000 | 683,027 | $44K | SEC Form 4 |
BMEA contract awards, year to date.
Public federal awards linked to this ticker.
BMEA lobbying filings, year to date.
Registered lobbying filings matched to Biomea Fusion Inc.